These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 8531503)

  • 1. Noradrenaline and Parkinson's disease.
    Delaville C; Deurwaerdère PD; Benazzouz A
    Front Syst Neurosci; 2011; 5():31. PubMed ID: 21647359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach.
    Lehr T; Staab A; Tillmann C; Nielsen EØ; Trommeshauser D; Schaefer HG; Kloft C
    Br J Pharmacol; 2008 Jan; 153(1):164-74. PubMed ID: 17982477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine transporter changes in neuropsychiatric disorders.
    Wong DF; Ricaurte G; Gründer G; Rothman R; Naidu S; Singer H; Harris J; Yokoi F; Villemagne V; Szymanski S; Gjedde A; Kuhar M
    Adv Pharmacol; 1998; 42():219-23. PubMed ID: 9327883
    [No Abstract]   [Full Text] [Related]  

  • 4. Positron emission tomography radioligands for dopamine transporters and studies in human and nonhuman primates.
    Volkow ND; Fowler JS; Ding YS; Wang GJ; Gatley SJ
    Adv Pharmacol; 1998; 42():211-4. PubMed ID: 9327881
    [No Abstract]   [Full Text] [Related]  

  • 5. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.
    Tatsch K
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):711-4. PubMed ID: 11976813
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter.
    Hume SP; Luthra SK; Brown DJ; Opacka-Juffry J; Osman S; Ashworth S; Myers R; Brady F; Carroll FI; Kuhar MJ; Brooks DJ
    Nucl Med Biol; 1996 Apr; 23(3):377-84. PubMed ID: 8782251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of imaging agents for the dopamine transporter.
    Carroll FI; Scheffel U; Dannals RF; Boja JW; Kuhar MJ
    Med Res Rev; 1995 Sep; 15(5):419-44. PubMed ID: 8531503
    [No Abstract]   [Full Text] [Related]  

  • 8. Single-photon emission tomography imaging of dopamine terminal innervation: a potential clinical tool in Parkinson's disease.
    Innis RB
    Eur J Nucl Med; 1994 Jan; 21(1):1-5. PubMed ID: 8088279
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine transporter: basic aspects and neuroimaging.
    Piccini PP
    Mov Disord; 2003 Oct; 18 Suppl 7():S3-8. PubMed ID: 14531039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging neurochemical endophenotypes: promises and pitfalls.
    Martinez D; Broft A; Laruelle M
    Pharmacogenomics; 2001 Aug; 2(3):223-37. PubMed ID: 11535111
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.